2022
Growth rate of ascending thoracic aortic aneurysms in a non-referral-based population
Weininger G, Mori M, Yousef S, Hur DJ, Assi R, Geirsson A, Vallabhajosyula P. Growth rate of ascending thoracic aortic aneurysms in a non-referral-based population. Journal Of Cardiothoracic Surgery 2022, 17: 14. PMID: 35109884, PMCID: PMC8812194, DOI: 10.1186/s13019-022-01761-6.Peer-Reviewed Original ResearchConceptsAneurysm growth rateAortic dilatationAortic aneurysmStudy populationCT scanInitial aneurysm sizeTrue natural historyPatients age 50High-risk patientsMedian time intervalLarge institutional databaseThoracic aortic aneurysmComputed tomography scanAortic aneurysm diseaseRisk patientsAortic sizeInstitutional databaseTomography scanAneurysm diseaseRadiologic diagnosisAneurysm sizeBackgroundPrior studiesAge 50PatientsNatural history
2021
Risk reduction and pharmacological strategies to prevent progression of aortic aneurysms
Weininger G, Chan SM, Zafar M, Ziganshin BA, Elefteriades JA. Risk reduction and pharmacological strategies to prevent progression of aortic aneurysms. Expert Review Of Cardiovascular Therapy 2021, 19: 619-631. PMID: 34102944, DOI: 10.1080/14779072.2021.1940958.Peer-Reviewed Original ResearchConceptsAortic aneurysmAbdominal aortic aneurysmß-blockersAngiotensin II receptor blockersAngiotensin-converting enzyme inhibitorAnti-platelet medicationDifferent pharmacologic therapiesII receptor blockersAortic aneurysm patientsThoracic aortic aneurysmRisk reductionAortic aneurysm growthPharmacologic managementReceptor blockersPharmacologic therapyMedical therapySurgical interventionAneurysm patientsMiscellaneous drugsAneurysm diseasePharmacological strategiesSyndrome patientsMarfan syndromeEnzyme inhibitorsAneurysms